Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5725170 | 0.82 | ALDH1A1 (0.36) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 | |
| SCHEMBL4903998 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 | |
| SCHEMBL4900718 | 0.79 | NPC1 (0.38) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 | |
| SCHEMBL5286858 | 0.77 | HPGD (0.40) | ALDH1A1LMNAPOLBSMN1; SMN2L3MBTL1 | |
| SCHEMBL17029332 | 0.76 | NPC1 (0.31) | ALDH1A1LMNAPOLBRAB9ANPC1 | |
| SCHEMBL15856269 | 0.74 | USP2 (0.38) | POLBL3MBTL1 | |
| SCHEMBL13827814 | 0.74 | CTSK (0.40) | CYP2C19CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13819886 | 0.72 | CCNE1 (0.32) | — | |
| SCHEMBL13827910 | 0.72 | NPPA (0.32) | — | |
| SCHEMBL5290177 | 0.72 | NPC1 (0.42) | ALDH1A1LMNAPOLBCYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1599454-B1 | DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-12-26 | — | — | EP | disclosed |
| US-7160911-B2 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1599454-A2 | DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040204462-A1 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-14 | — | — | US | disclosed |
| WO-2004075815-A2 | DIARYLCYCLOALKYL DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204462-A1 | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | GPR119, HSD17B14, SLC2A1 | ALDH1A1 294/4885LMNA 2583/4885POLB 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.